Clinical Trials Logo

Clinical Trial Summary

POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular Systems (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.


Clinical Trial Description

POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular System (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease. This study will enroll subjects >18 years old that are presenting for a peripheral arterial disease intervention for the treatment of peripheral artery disease. Specifically, the subject has moderate to heavily calcified superficial femoral and popliteal arteries, presenting with Rutherford Category 2 to 4 of the target limb, with a reference vessel diameter (RVD) of 4mm to 6.5mm and a total lesion length of ≤ 150mm. Up to 120 subjects will be treated in the study at up to 20 U.S. investigational sites. Subjects will be evaluated at discharge, 30 days and 6 months after procedure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06457685
Study type Interventional
Source Amplitude Vascular Systems, Inc.
Contact Beatriz Vendrell-Velez
Phone 210-414-2646
Email bvendrell-velez@avspulse.com
Status Not yet recruiting
Phase N/A
Start date August 2024
Completion date March 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01175850 - Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease N/A
Active, not recruiting NCT00707876 - Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD) Phase 2
Completed NCT00760565 - A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD). Phase 1
Recruiting NCT04631848 - ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease
Completed NCT00196066 - Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS) Phase 2
Recruiting NCT05834673 - VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) Phase 4
Recruiting NCT05498740 - Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia N/A
Completed NCT02780349 - Evaluation of WIRION™ EPS in Lower Extremities Arteries N/A
Completed NCT02254356 - Zilver Flex Post-Market Study in Japan N/A
Completed NCT02254837 - Zilver PTX Post-Market Study in Japan N/A
Completed NCT00689377 - Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention N/A
Active, not recruiting NCT05149664 - A Non-significant Risk Clinical Study: Changes in Perfusion After Therapeutic Ultrasound in Patients With PAD N/A
Recruiting NCT04749732 - Home-based Exercise Therapy for Patients With PAD N/A
Completed NCT02936622 - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses N/A
Completed NCT00827619 - Zilver® Flex™ Vascular Stent Study N/A
Completed NCT00862420 - Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease Phase 3
Completed NCT04753372 - Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Recruiting NCT05246410 - A Clinical Trial to Evaluate the Efficacy and Safety of a Spot Stent System Used in Femoropopliteal Arteries. N/A
Terminated NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Phase 3
Terminated NCT03174522 - The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Phase 3